NRIX · Sanofi notified Nurix that it is discontinuing the Phase 1 trial of…

Sanofi notified Nurix that it is discontinuing the Phase 1 trial of SAR448272 (an oral STAT6 degrader) and terminating the program. Nurix will not receive any future milestone payments or royalties tied to SAR448272, but remains eligible for payments on other Sanofi collaboration programs.

• Sanofi notified Nurix of its decision to discontinue the Phase 1 trial of SAR448272 and terminate the program.
• Nurix will not receive any future development, regulatory or commercial milestone payments or royalties for SAR448272.
• Nurix remains eligible for milestone payments and royalties on other licensed programs under the Sanofi collaboration.
• The filing does not disclose the financial terms of the Sanofi collaboration or the specific value of lost milestones for SAR448272.